KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Taxes (2020 - 2022)

AbCellera Biologics (ABCL) has disclosed Current Taxes for 3 consecutive years, with $23.0 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Current Taxes rose 249.29% year-over-year to $23.0 million, compared with a TTM value of $23.0 million through Sep 2022, up 249.29%, and an annual FY2021 reading of $35.7 million, down 1.3% over the prior year.
  • Current Taxes was $23.0 million for Q3 2022 at AbCellera Biologics, down from $107.3 million in the prior quarter.
  • Across five years, Current Taxes topped out at $107.3 million in Q2 2022 and bottomed at $5.8 million in Q2 2021.
  • Average Current Taxes over 3 years is $43.8 million, with a median of $32.9 million recorded in 2021.
  • The sharpest move saw Current Taxes decreased 1.3% in 2021, then soared 1743.39% in 2022.
  • Year by year, Current Taxes stood at $36.2 million in 2020, then fell by 1.3% to $35.7 million in 2021, then plummeted by 35.49% to $23.0 million in 2022.
  • Business Quant data shows Current Taxes for ABCL at $23.0 million in Q3 2022, $107.3 million in Q2 2022, and $105.6 million in Q1 2022.